Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Non Small Cell Lung Cancer Clinical Trial

Official title: a Clinical Trial Phase II Prospective, Single-arm Study of Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced Non-small Cell Lung Cancer

Status Not yet recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of recombinant human endostatin /PD-1 mab combined with first-line chemotherapy in the treatment of driver gene negative advanced non-small cell lung cancer.

Clinical Trial Description

This study is planned to enroll 38 eligible patients in China. Patients who fulfill all the inclusion criteria and none of the exclusion criteria will receive 4-6 cycles of endostatin combined with PD-1 antibody and platinum-containing two-drug chemotherapy.The efficacy of first-line treatment was evaluated every 6 weeks (2 cycles, 42 days). Patients with disease control (CR+ PR+SD) and tolerable adverse reactions were treated for 4-6 cycles,The maintenance treatment phase was continuous treatment with Endu combined with PD-1 antibody, and the efficacy was evaluated every 9 weeks until the end of the study when the investigator considered that the patient was not suitable for continued medication or the efficacy evaluation was disease progression (PD). No other antitumor therapy can be performed during the treatment period. Follow-up of survival was once every 3 months. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Endostatin
• Lung Neoplasms
• Non Small Cell Lung Cancer

• NCT number: NCT05448781
• Study type: Interventional
• Source: Affiliated Cancer Hospital & Institute of Guangzhou Medical University
• Contact: Chuan Jin
• Phone: 020-66673634
• Email: jinchuan5959@163.com
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 20, 2022
• Completion date: December 20, 2023